2021
Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
Lee G, Nagaya N, Desantis J, Madura K, Sabaawy H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 2021, 20: 490-499. PMID: 33277442, DOI: 10.1158/1535-7163.mct-20-0417.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerSecond-line antiandrogen therapyAR full lengthAndrogen receptor splice variant 7AR-V7Antiandrogen therapyAndrogen-responsive prostate cancer cellsProstate cancer cellular proliferationHuman prostate cancer cell linesProstate cancer cell linesStandard of careCancer cellular proliferationCellular proliferationPotential therapeutic valueProstate cancer cellsAgents abirateroneCancer cell linesProteolysis Targeting ChimerasMechanisms of resistanceAndrogen receptorAR DNAProstate cancerTumor growthTherapeutic valueAntiproliferative effects
2019
Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL
Lee G, Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 2019, 160: 2049-2060. PMID: 31184711, PMCID: PMC6691685, DOI: 10.1210/en.2019-00367.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyCell linesHuman peripheral blood monocytesMetastatic prostate cancerPotential treatment optionPeripheral blood monocytesCytotoxicity of macrophagesHuman monocyte cell lineProstate cancer cellsCaP cell linesMonocyte cell lineVivo mouse studiesCytotoxic activityMurine macrophage cell lineApoptosis-inducing ligandConcentration-dependent mannerDeprivation therapyClodronate liposomesTreatment optionsM1 polarizationCaP tumorsAndrogen receptorMacrophage cell lineProstate cancerImmune response
2016
BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research 2016, 22: 6176-6191. PMID: 27307599, PMCID: PMC5159329, DOI: 10.1158/1078-0432.ccr-15-3107.Peer-Reviewed Original ResearchConceptsTumor-initiating cellsProstate tumor-initiating cellsBmi-1Androgen receptor-directed therapyIntrinsic therapy resistanceReceptor-directed therapyProstate cancer managementProstate cancer treatmentMore effective therapiesBmi-1 expressionProstate cancer cellsStem cell-like traitsSelf-renewing tumor-initiating cellsCell-like traitsPatient-derived cellsEffective therapyTumor relapseCancer managementXenograft modelTherapy resistancePharmacologic inhibitionBmi-1 functionTherapyNormal tissuesCancer treatment
2013
Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages
Lee G, Jung Y, Ha Y, Kim J, Kim W, Kim I. Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Science 2013, 104: 1027-1032. PMID: 23710822, PMCID: PMC7657257, DOI: 10.1111/cas.12206.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen Receptor AntagonistsAndrogensAnilidesAnimalsBenzamidesBenzofuransBone Morphogenetic Protein 6Cell Line, TumorDihydrotestosteroneHumansInterleukin-6Lymphocytes, Tumor-InfiltratingMacrophagesMaleMiceNitrilesPhenylthiohydantoinPromoter Regions, GeneticProstatic Neoplasms, Castration-ResistantQuinolinesReceptors, AndrogenTosyl CompoundsUp-RegulationConceptsCaP cell linesCastration resistanceInterleukin-6Castration-resistant prostate cancerContext of macrophagesHuman CaP cell linesExpression of ARRemoval of macrophagesAndrogen receptor mRNAProstate cancer progressionBMP-6Presence of dihydrotestosteroneProstate cancer cellsCell linesPresence of macrophagesPleiotropic growth factorBone morphogenetic proteinClodronate liposomesTRAMP-C1AR upregulationProstate cancerAndrogen hypersensitivityMacrophage coculturesReceptor mRNACell count
2011
Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 Loop
Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Lee D, Kim I. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 Loop. The Prostate 2011, 71: 1525-1537. PMID: 21374653, DOI: 10.1002/pros.21369.Peer-Reviewed Original ResearchConceptsProstate cancer cellsHormone-refractory prostate cancerRefractory prostate cancerNeuroendocrine differentiationBone morphogenetic protein 6IL-6Cancer cellsProstate cancerInterleukin-6 knockout miceTRAMP-C2 cell lineHuman prostate cancer tissuesNeuroendocrine cellsCell linesParathyroid hormone-related peptideTRAMP-C2 prostate cancer cellsTRAMP-C2 cellsMacrophage-depleted miceProstate Cancer Neuroendocrine DifferentiationIL-6 expressionTHP-1 human monocytic cell lineHormone-related peptideProstate cancer tissuesHuman monocytic cell lineRAW 264.7 murine macrophage cell lineEffect of macrophages
2004
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells
Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.Peer-Reviewed Original ResearchConceptsBone morphogenetic proteinProstate cancer cellsHuman prostate cancer cellsLoss of expressionProstate cancer patientsBMP-RIICancer patientsGleason scoreBMP receptor type IABone morphogenetic protein receptor type IICancer cellsSignificant associationHuman prostate cancer cell linesBiochemical recurrence-free rateExpression of BMPRsRecurrence-free rateProstate cancer cell linesCell linesTumor growth rateReceptor type IIParental cell lineCancer cell linesMorphogenetic proteinsClinical stagePrognostic value
1998
Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1
Rohlff C, Blagosklonny M, Kyle E, Kesari A, Kim I, Zelner D, Hakim F, Trepel J, Bergan R. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. The Prostate 1998, 37: 51-59. PMID: 9721069, DOI: 10.1002/(sici)1097-0045(19980915)37:1<51::aid-pros8>3.0.co;2-b.Peer-Reviewed Original ResearchConceptsProstate cancer cell growthCancer cell growthProtein kinase CHormone-refractory prostate cancerProstate cancer cell growth inhibitionGrowth inhibitionInhibition of PKCG1/S phase cell cycle arrestTamoxifen-mediated growth inhibitionCancer cell growth inhibitionProstate cancer cellsPhase cell cycle arrestDU145 prostate cancer cellsS-phase cell cycle arrestRetinoblastoma protein levelsFlow cytometric analysisP21WAF1/CIP1Cell growth inhibitionTamoxifen treatmentCell cycle arrestCell growthProstate cancerKinase CCytometric analysisWestern blot
1996
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.
Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. PMID: 9816295.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsAntibody SpecificityHumansImmunohistochemistryMaleProstatic NeoplasmsProtein Serine-Threonine KinasesRabbitsReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTumor Cells, CulturedConceptsType II receptorHuman prostate cancer tissuesProstate cancer tissuesII receptorsProstate cancer cellsLoss of expressionTumor gradeTGF-beta receptorsCancer tissuesProstate tissueTGF-beta1 type IProstate cancer cell growthMalignant human prostate tissueType ICancer cellsHuman prostate cancer cellsGrowth factor-beta type IProstate cancer casesHuman prostate cancerBenign prostate tissueCancer cell growthHuman prostate tissueTGF-beta type IGrowth factor beta1Benign human prostateModulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone
Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone. Experimental Cell Research 1996, 222: 103-110. PMID: 8549651, DOI: 10.1006/excr.1996.0013.Peer-Reviewed Original ResearchMeSH KeywordsBinding, CompetitiveCell CountCell DivisionDihydrotestosteroneDNA, NeoplasmHumansMalePromoter Regions, GeneticProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTranscriptional ActivationTransforming Growth Factor betaTumor Cells, CulturedConceptsTGF-beta receptor type IILNCaP cellsReceptor type IIAndrogen-responsive prostate cancerCharcoal-stripped fetal bovine serumEffect of dihydrotestosteroneGrowth factor-β1Type II TGF-β receptorProstate cancer cellsGrowth inhibitory effectsTGF-β receptorWestern blot analysisDHT concentrationsPresent studyType IIModulation of sensitivityProstate cancerAndrogenic conditionsFactor-β1DihydrotestosteronePotential physiological regulatorsInhibitory effectGene transcriptional activityCancer cellsPhysiological regulatorGenetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. PMID: 8548772.Peer-Reviewed Original ResearchConceptsProstate cancer cell linesLNCaP cellsProstate cancer cellsType I receptorT beta RCancer cell linesI geneDU145 cellsGenetic changesTGF-beta receptor type III receptorTGF-beta receptor expressionGrowth factor beta 1Beta RCancer cellsHuman prostate cancer cellsProliferation of PC3TGF-beta signalsBlot analysisReceptor type IICell linesDose-dependent mannerSouthern blot analysisType I geneType II receptor
1995
Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. DOI: 10.1210/en.136.2.796.Peer-Reviewed Original ResearchProstate-specific antigenProduction of prostate-specific antigenProstate-specific antigen secretionConcentrations of dihydrotestosteroneEffects of androgensDihydrotestosterone concentrationsAndrogen receptorAndrogen-sensitive human prostate cancer cell lineAndrogen-sensitive prostate cancer cellsIncreasing concentrations of DHTLow concentrations of dihydrotestosteroneCharcoal-stripped fetal bovine serumAnalysis of androgen receptorHuman prostate cancer cell linesProstate cancer cell linesCellular proliferationProstate cancer cellsNuclear androgen receptorAmount of receptor proteinDose-dependent inductionProportion of cellsFetal bovine serumCancer cell linesLNCaP cellsRegulation of proliferation